Masters Speciality Pharma is pleased to announce its appointment as Amgen (Europe) GmbH’s exclusive supplier of XGEVA® (denosumab), Prolia® (denosumab) and Neupogen® (filgrastim), to government bodies, hospitals and Health Care Professionals in the selected countries below.
XGEVA® (denosumab) is indicated for the prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumours.
Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
Presentation: 120 mg solution (in a vial) for injection.
Prolia® (denosumab) is indicated for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Prolia significantly reduces the risk of vertebral, non-vertebral and hip fractures.
Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures (see section 5.1). In men with prostate cancer receiving hormone ablation, Prolia significantly reduces the risk of vertebral fractures.
Presentation: pre-filled syringe contains 60 mg of denosumab in 1 ml of solution (60 mg/ml).
Neupogen® (filgrastim) is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.
Presentation: Neupogen Singleject 30 MU (0.6 mg/ml) solution for injection in a pre-filled syringe filgrastim.
Masters Speciality Pharma’s expertise and experience in the supply of important medicinal products to countries around the world spans more than 30 years’, and to this day, the supply of medicines for Patients in countries where there are unmet needs for the medication, in a manner that is compliant with the applicable country regulations and Good Distribution Practices, remains the Company’s priority.
Amgen is one of the world’s leading biotechnology companies. It is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses. The Company’s mission is to “serve patients”.
Patients and Healthcare Professionals wishing to know more about the availability of XGEVA® (denosumab), Prolia® (denosumab) and Neupogen® (filgrastim), in the countries above should contact Masters Speciality Pharma:
Phone: +44 (0)208 327 0900
Fax: +44 (0)208 327 0901